Launch of Inhalytix®+ v2.0 and the new Critical Flow Controller TPK 200iX demonstrate a future-facing, digital testing environment.
02 September 2026; Nottingham, UK: Copley, the global leader in inhaler testing solutions, has marked a significant milestone in connected, digitised inhaler testing with the unveiling of Inhalytix+ v2.0 and the new Critical Flow Controller TPK 200iX.
The innovations show how Copley is shaping the future of inhaler testing, addressing long-standing challenges around fragmented workflows, manual data handling, disconnected systems and information silos. They exemplify the company’s unique ability to combine specialist equipment, software, automation, services and technical expertise to optimise inhaler testing practice. With Inhalytix+ v2.0 as a powerful digital hub and the TPK 200iX delivering advanced and extended method control, Copley is helping laboratories build connected capability in a practical, stepwise way.
‘The inhaler testing laboratory is changing,’ said Paul Martin, Head of Business Development. ‘Customers need greater confidence in their results and the workflows delivering them. Stronger method control, fewer sources of variability and rigorous data management are becoming essential to progress efficiently and demonstrate the robust consistency and integrity that regulators are looking for. Inhalytix+ v2.0 and the TPK 200iX enable implementation of the connected inhaler testing workflows needed to realise these goals and reflect a broader direction of travel towards more consistent testing performance.’
This substantial launch demonstrates how Copley will deliver next generation, digitalised inhaler testing performance and reinforces their ability to do so.
Inhalytix+ V2.0 offers a controlled digital environment for inhaler testing. It provides a framework for laboratories seeking greater reliability and traceability across the inhaler testing workflow, from method set-up to review and reporting. It streamlines and enhances testing by:
- connecting directly to equipment, driving testing and drawing critical data into the wider centralising method and workflow management, supporting consistent set-up, review and reporting.
- linking test equipment information such as mensuration and calibration data to the test record, helping laboratories maintain clear visibility of equipment condition and strengthen traceability.
- expanding data review options, adding enhanced graphical outputs and customisable reports.
- establishing role-based access, audit trails and structured sign-off, safeguarding regulated laboratory workflows and electronic recordkeeping.
The new TPK 200iX realises the potential of connected workflows via first-in-class two-way connectivity. Successor to the industry-standard TPK 100i, it combines enhanced, patent-pending flow control capability with digital method control. When connected with Inhalytix+ v2.0, it enables approved methods and authorised user permissions to be made available on connected TPK 200iX units, while operating information and reports are returned to the wider digital test record. Key advances include:
- broader critical flow control capability: with extended run time, lower flow-rate capability and enhanced workflow visibility.
- guided test set-up: an all-new user experience guides analysts step-by-step through test set-up and operation, supporting more consistent critical flow control workflows.
- returned reports and operating information: helping build a clearer digital record of critical flow control activity.
‘This launch reflects where inhaler testing is heading: towards more connected workflows that are traceable, transferable, and scalable,’ concludes Paul. ‘By combining specialist equipment, powerful software and technical know-how we are helping laboratories strengthen the complete testing workflow, giving customers the practical tools to build connected capability at a pace that suits their laboratory.’
To find out more about the Inhalytix+ v2.0 and the Critical Flow Controller TPK 200iX and their ability to enhance inhaler testing, contact the Copley team.
Inhalytix®+ v2.0 and the TPK 200iX work together to connect centrally managed methods and users with connected equipment, critical flow control activity and the wider digital test record.
About Copley Scientific
Copley Scientific is widely recognised as the world’s leading provider of inhaler testing solutions and is a major supplier of testing systems for other pharmaceutical dosage forms. The company also supplies equipment for detergent testing.
Copley’s inhaler testing portfolio supports all types of orally inhaled and nasal drug products, including metered-dose inhalers, dry powder inhalers, nebulisers and nasal products. Its solutions span delivered dose uniformity and aerodynamic particle size distribution measurement, combining specialist testing equipment with software, automation, accessories and support services to help laboratories build controlled, consistent and increasingly connected testing workflows.
It’s wider pharmaceutical testing product range also includes testers for tablets (dissolution, disintegration, friability and hardness), capsules, powders, suppositories, semisolids and transdermals.
Used from R&D through to QC, Copley’s product and solutions portfolio is supported by a full validation and aftersales service. Copley works in partnership with specialist distributors, extending localised support across the world. This network provides expert help and training to every customer. www.copleyscientific.com
For further information
Press information/Company contact:
Rosanna Kelly, Marketing Manager
Copley Scientific Limited
Colwick Quays Business Park, Road No. 2, Nottingham, NG4 2JY, UK
Tel: +44 (0)115 961 6229
mediarelations@copleyscientific.co.uk
